AMP expands into Parkinson's
NIH's Accelerating Medicines Partnership (AMP), a public-private partnership focused on identifying and validating new disease targets and biomarkers, announced a five-year, $24 million expansion into Parkinson's disease that builds on a biomarker study run by the Michael J. Fox Foundation For Parkinson's Research (New York, N.Y.).
MJFF, along with industry partners Celgene Corp. (NASDAQ:CELG), GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), Sanofi (Euronext:SAN; NYSE:SNY) and Pfizer Inc. (NYSE:PFE), will contribute a total of $10 million to the program. Verily Life Sciences LLC (South San Francisco, Calif.) is to provide an additional $2 million in-kind contribution in data analysis software and services. NIH will match with an additional $12 million...